Lantheus/LNTH

$60.79

-1.04%
-
1D1W1MYTD1YMAX

About Lantheus

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.

Ticker

LNTH

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Mary Heino

Employees

834

Headquarters

North billerica, United States

Lantheus Metrics

BasicAdvanced
$4.17B
Market cap
13.10
P/E ratio
$4.64
EPS
0.55
Beta
-
Dividend rate
$4.17B
0.5503
$100.85
$50.20
1.02M
5.796
5.454
68.841
68.942
13.623
1,235.43%
21.98%
51.73%
25.75%
13.097
3.214
5.106
6.914
19.532
38.65%
1,252.73%
56.32%

What the Analysts think about Lantheus

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
59.73% upside
High $128.00
Low $82.00
$60.79
Current price
$97.10
Average price target

Lantheus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
29.18% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$353.9M
10.63%
Net income
$103.3M
-21.68%
Profit margin
29.18%
-29.23%

Lantheus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.42%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$1.47
$1.54
$1.47
$1.75
-
Expected
$1.26
$1.31
$1.32
$1.45
$1.55
Surprise
16.92%
17.52%
11.12%
20.42%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Lantheus stock?

Lantheus (LNTH) has a market cap of $4.17B as of April 14, 2024.

What is the P/E ratio for Lantheus stock?

The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 13.1 as of April 14, 2024.

Does Lantheus stock pay dividends?

No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Lantheus dividend payment date?

Lantheus (LNTH) stock does not pay dividends to its shareholders.

What is the beta indicator for Lantheus?

Lantheus (LNTH) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Lantheus stock price target?

The target price for Lantheus (LNTH) stock is $97.1, which is 59.73% above the current price of $60.79. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Lantheus stock

Buy or sell Lantheus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing